3 Biotech Stocks to Buy ASAP

Oversold obesity stocks are a prime opportunity [Morning Watchlist] You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please [unsubscribe]( here.  Prefer to view this content on our website? [Click here.]( --------------------------------------------------------------- Dear Fellow Investor, Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly, for example. --------------------------------------------------------------- Company: Eli Lilly (SYM: LLY) The last time I mentioned LLY, I said, “Oversold shares of Eli Lilly could easily bounce higher on sales of its obesity drugs. And it could easily jump higher with its Zepbound drug being considered for the treatment of sleep apnea.” That was on July 30, as the stock traded at about $780. Today, it’s already up to $893.04 and could easily push aggressively higher thanks to growing demand for its obesity treatments and strong earnings. And, again thanks to obesity treatments, it raised guidance well above estimates. --------------------------------------------------------------- Millionaire Publishing [Got 14 minutes?](Then you have time to learn the unusual market loophole Tim Sykes uses to earn $8,780, $9,518 and even $16,159 on the weekend. (While the market is closed) [Watch the amazing 14 min video now.]( --------------------------------------------------------------- However, LLY isn’t the only obesity treatment stock worth paying attention to. There’s also: Company: Viking Therapeutics (SYM: VKTX) Now trading at $57, VKTX could run back to all-time highs, as it nears Phase 3 trials for its obesity treatment, VK2735. The company just announced plans to start a late-stage trial for its obesity drug VK2735 later this year. “We are advancing this compound into Phase 3 development,” CEO Brian Lian said, as noted in a company press release, adding that “we are currently preparing for an end-of-phase 2 meeting with the agency, which we expect to occur later this year.” In addition, Phase 1 trials of the oral form of the treatment showed encouraging safety and tolerability, with positive signs of clinical activity, as noted in a company press release. Patients also reported a mean weight loss of up to 5.3% from baseline after 28 days. The company expects to move into Phase 2 with the oral treatment later this year. --------------------------------------------------------------- Simpler Trading [FREE training: The day trading strategy behind Tr3ndy Jon’s +80% win rate]( What if you could anticipate major market turns … even in highly volatile conditions that appear “random”? The “Big Players” are behind the big moves, but most traders don’t know how to read their order flow. We’ll show you how to do this with my “supply and demand” day trading system. Using this strategy, we’re seeing an +80% win rate. Want to learn more? [Check out my FREE training here.]( --------------------------------------------------------------- Company: Structure Therapeutics (SYM: GPCR) The company recently reported positive topline data from its Phase 2a obesity study of GSBR-1290, which “demonstrated a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks,” according to a company press release. GPCR is also on track to initiate a 36-week Phase 2b study of GSBR-1290 in the fourth quarter of the year. Should it continue to show solid progress, shares of GPCR could easily push aggressively higher. Even better, JPMorgan analysts noted: “We think the opportunity for oral GLP-1s is underappreciated and think this market could generate $30bn in sales by 2035. GPCRs lead asset, 1290, is a pure-play option for this opportunity, and even a small share would support substantial upside to the stock.” --------------------------------------------------------------- Financial Newsletter Team [Top 4 Gold Stocks for August](FREE Report: Top 4 Gold Stocks Ready to Surge as Gold Prices Climb Higher Gold has recently soared to new all-time highs and appears poised to climb even higher. Given this massive gold bull market, how should you invest for maximum potential upside? [Click here to download your copy of this Free Report detailing the 4 leading gold stocks that are positioned to surge as gold prices continue their upward trajectory]( (By clicking the links above, you agree to receive emails from us and our partners. You can opt out at any time.) --------------------------------------------------------------- [Join Daily Guru Trades!]( Want more free daily trades in your inbox? [Sign up for Dylan Jovine's Daily Guru Trades Today.]( Do you currently own shares of obesity treatment biotech stocks? Do you have your eye on any other under-the-radar biotech stocks we might have missed? Hit "reply" to this email and let us know! Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Behind the Markets](  [Unsubscribe]( Â